This article has been cited by
1Tuberculosis: Still a Way to go ahead for a Lead- A Review
Priyanka Bose,Amit K Harit,Kamal Krishna Halder
Journal of Analytical & Pharmaceutical Research.2017;5(6)
[DOI]
2Targeting the Serine Pathway: A Promising Approach against Tuberculosis?
Marie Haufroid,Johan Wouters
Pharmaceuticals.2019;12(2)66
[DOI]
3In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates
Yuvaraj Chandramohan,Venkatesan Padmanaban,Ramalingam Bethunaickan,Srikanth Tripathy,Soumya Swaminathan,Uma Devi Ranganathan
Journal of Global Antimicrobial Resistance.2019;19(2)348
[DOI]
4New prodrugs against tuberculosis
Giorgia Mori,Laurent Roberto Chiarelli,Giovanna Riccardi,Maria Rosalia Pasca
Drug Discovery Today.2017;22(3)519
[DOI]
5News on therapeutic management of MDR-tuberculosis: a literature review
Lucie Barthod,Jean-Guillaume Lopez,Christophe Curti,Charléric Bornet,Manon Roche,Marc Montana,Patrice Vanelle
Journal of Chemotherapy.2018;30(1)1
[DOI]
6Strategies towards the synthesis of anti-tuberculosis drugs
Haridas B. Rode,Dhanaji M. Lade,René Grée,Prathama S. Mainkar,Srivari Chandrasekhar
Organic & Biomolecular Chemistry.2019;17(22)5428
[DOI]
7Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity
Angie M. Jarrad,Chee Wei Ang,Anjan Debnath,Hye Jee Hahn,Kyra Woods,Lendl Tan,Melissa L. Sykes,Amy J. Jones,Ruby Pelingon,Mark S. Butler,Vicky M. Avery,Nicholas P. West,Tomislav Karoli,Mark A. T. Blaskovich,Matthew A. Cooper
Journal of Medicinal Chemistry.2018;61(24)11349
[DOI]
8What is New in Management of Pediatric Tuberculosis ?
Alkesh Kumar Khurana,Bhavna Dhingra
Indian Pediatrics.2019;56(3)213
[DOI]
9Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase
Andrei L. Osterman,Irina Rodionova,Xiaoqing Li,Eduard Sergienko,Chen-Ting Ma,Antonino Catanzaro,Mark E. Pettigrove,Robert W. Reed,Rashmi Gupta,Kyle H. Rohde,Konstantin V. Korotkov,Leonardo Sorci
ACS Chemical Biology.2019;14(5)949
[DOI]
10Screening of natural compounds that targets glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids
Alka Pawar,Prakash Jha,Madhu Chopra,Uma Chaudhry,Daman Saluja
Scientific Reports.2020;10(1)949
[DOI]
11Mycobacterial protein tyrosine kinase, PtkA phosphorylates PtpA at tyrosine residues and the mechanism is stalled by the novel series of inhibitors
Swati Jaiswal,Aditi Chatterjee,Sapna Pandey,Kiran Lata,Ranjith Kumar Gadi,Rajesh Manda,Sanjay Kumar,Maddi Sridhar Reddy,Ravishankar Ramachandran,Kishore K. Srivastava
Journal of Drug Targeting.2019;27(1)51
[DOI]
12The anti-tuberculosis agents under development and the challenges ahead
Deepak Kumar,Beena Negi,Diwan S Rawat
Future Medicinal Chemistry.2015;7(15)1981
[DOI]
13The anti-tuberculosis agents under development and the challenges ahead
Ashima Bhaskar,Ved Prakash Dwivedi,Vinay Kumar Nandicoori
Future Medicinal Chemistry.2019;7(15)57
[DOI]
14In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy
T. Parumasivam,J. G. Y. Chan,A. Pang,D. H. Quan,J. A. Triccas,W. J. Britton,H. K. Chan
Molecular Pharmaceutics.2016;13(3)979
[DOI]
151H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis
Malgorzata Korycka-Machala,Albertus Viljoen,Jakub Pawelczyk,Paulina Borówka,Bozena Dziadek,Katarzyna Gobis,Anna Brzostek,Malwina Kawka,Mickael Blaise,Dominik Strapagiel,Laurent Kremer,Jaroslaw Dziadek
Antimicrobial Agents and Chemotherapy.2019;63(10)979
[DOI]
16Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study
Yesha S. Patel,Sarika Mehra
Frontiers in Microbiology.2017;8(10)979
[DOI]
17Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis
W. David Hong,Peter D. Gibbons,Suet C. Leung,Richard Amewu,Paul A. Stocks,Andrew Stachulski,Pedro Horta,Maria L. S. Cristiano,Alison E. Shone,Darren Moss,Alison Ardrey,Raman Sharma,Ashley J. Warman,Paul T. P. Bedingfield,Nicholas E. Fisher,Ghaith Aljayyoussi,Sally Mead,Maxine Caws,Neil G. Berry,Stephen A. Ward,Giancarlo A. Biagini,Paul M. O’Neill,Gemma L. Nixon
Journal of Medicinal Chemistry.2017;60(9)3703
[DOI]
18Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases
Chee Wei Ang,Angie M. Jarrad,Matthew A. Cooper,Mark A. T. Blaskovich
Journal of Medicinal Chemistry.2017;60(18)7636
[DOI]
19Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds
Guilherme Fernandes,Chung Man Chin,Jean Dos Santos
Pharmaceuticals.2017;10(4)51
[DOI]
20NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G
Saqib Kidwai,Rania Bouzeyen,Sohini Chakraborti,Neha Khare,Sumana Das,Tannu Priya Gosain,Assirbad Behura,Chhuttan Lal Meena,Rohan Dhiman,Makram Essafi,Avinash Bajaj,Deepak Kumar Saini,Narayanaswamy Srinivasan,Dinesh Mahajan,Ramandeep Singh
Antimicrobial Agents and Chemotherapy.2019;63(9)51
[DOI]
21An overview of new antitubercular drugs, drug candidates, and their targets
Aparna Bahuguna,Diwan S. Rawat
Medicinal Research Reviews.2020;40(1)263
[DOI]
22QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity
Marcelo N. Gomes,Rodolpho C. Braga,Edyta M. Grzelak,Bruno J. Neves,Eugene Muratov,Rui Ma,Larry L. Klein,Sanghyun Cho,Guilherme R. Oliveira,Scott G. Franzblau,Carolina Horta Andrade
European Journal of Medicinal Chemistry.2017;137(1)126
[DOI]
23Management of drug resistantTB in patients with HIV co-infection
Emanuele Pontali,Giovanni Sotgiu,Rosella Centis,Lia D’Ambrosio,Antonio Spanevello,Giovanni Battista Migliori
Expert Opinion on Pharmacotherapy.2015;16(18)2737
[DOI]
24Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents
Jie Liu,Zhenghong Ren,Li Fan,Jianyong Wei,Xuemei Tang,Xingran Xu,Dacheng Yang
Bioorganic & Medicinal Chemistry.2019;27(1)175
[DOI]
25Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti-tuberculosis activity
Naasson Tuyiringire,Deusdedit Tusubira,Jean-Pierre Munyampundu,Casim Umba Tolo,Claude M. Muvunyi,Patrick Engeu Ogwang
Clinical and Translational Medicine.2018;7(1)175
[DOI]
26Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB
Kaksha Sankhe,Tabassum Khan,Chintan Bhavsar,Munira Momin,Abdelwahab Omri
Expert Opinion on Drug Delivery.2019;16(5)525
[DOI]
27

Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture

Markos Tadele,Solomon M Abay,Eyasu Makonnen,Asrat Hailu
Drug Design, Development and Therapy.2020;Volume 14(5)1307
[DOI]
28Hit and lead criteria in drug discovery for infectious diseases of the developing world
Kei Katsuno,Jeremy N. Burrows,Ken Duncan,Rob Hooft van Huijsduijnen,Takushi Kaneko,Kiyoshi Kita,Charles E. Mowbray,Dennis Schmatz,Peter Warner,B. T. Slingsby
Nature Reviews Drug Discovery.2015;14(11)751
[DOI]
29Comparative genomics shows differences in the electron transport and carbon metabolic pathways of Mycobacterium africanum relative to Mycobacterium tuberculosis and suggests an adaptation to low oxygen tension
Boatema Ofori-Anyinam,Abi Janet Riley,Tijan Jobarteh,Ensa Gitteh,Binta Sarr,Tutty Isatou Faal-Jawara,Leen Rigouts,Madikay Senghore,Aderemi Kehinde,Nneka Onyejepu,Martin Antonio,Bouke C. de Jong,Florian Gehre,Conor J. Meehan
Tuberculosis.2020;120(11)101899
[DOI]
30Nitroimidazole-containing compounds and their antibacterial and antitubercular activities
Jingyu Zhang,Yanyan Ba,Su Wang,Huaixia Yang,Xuehui Hou,Zhi Xu
European Journal of Medicinal Chemistry.2019;179(11)376
[DOI]
31A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity
Sutharsana Yathursan,Siouxsie Wiles,Hannah Read,Vijayalekshmi Sarojini
Journal of Peptide Science.2019;25(11)376
[DOI]
32New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers
Serge Mignani,Rama Tripathi,Liang Chen,Anne-Marie Caminade,Xiangyang Shi,Jean-Pierre Majoral
Pharmaceutics.2018;10(3)105
[DOI]
33Drug development against tuberculosis: Impact of alkaloids
Shardendu K. Mishra,Garima Tripathi,Navneet Kishore,Rakesh K. Singh,Archana Singh,Vinod K. Tiwari
European Journal of Medicinal Chemistry.2017;137(3)504
[DOI]
34Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona sp.
Wilmar Maarisit,Delfly B. Abdjul,Hiroyuki Yamazaki,Hajime Kato,Henki Rotinsulu,Defny S. Wewengkang,Deiske A. Sumilat,Magie M. Kapojos,Kazuyo Ukai,Michio Namikoshi
Bioorganic & Medicinal Chemistry Letters.2017;27(15)3503
[DOI]
35Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona sp.
Maria Krutikov,Judith Bruchfeld,Giovanni Battista Migliori,Sergey Borisov,Simon Tiberi
Bioorganic & Medicinal Chemistry Letters.2018;27(15)179
[DOI]
36Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Vahid Lohrasbi,Malihe Talebi,Abed Zahedi Bialvaei,Lanfranco Fattorini,Michel Drancourt,Mohsen Heidary,Davood Darban-Sarokhalil
Tuberculosis.2018;109(15)17
[DOI]
37Roles of Fluorine in Drug Design and Drug Action
Satya Prakash Gupta
Letters in Drug Design & Discovery.2019;16(10)1089
[DOI]
38Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions
Monika Gaba,Chander Mohan
Medicinal Chemistry Research.2016;25(2)173
[DOI]
39Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis
Priya Singh,Rashmi Kumari,Rup Lal
Indian Journal of Microbiology.2017;57(4)371
[DOI]
40Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
André Campaniço,Rui Moreira,Francisca Lopes
European Journal of Medicinal Chemistry.2018;150(4)525
[DOI]
41Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Yu Zhou,Jiang Wang,Zhanni Gu,Shuni Wang,Wei Zhu,José Luis Aceña,Vadim A. Soloshonok,Kunisuke Izawa,Hong Liu
Chemical Reviews.2016;116(2)422
[DOI]
42Anti-Mycobacterial Nucleoside Antibiotics from a Marine-Derived Streptomyces sp. TPU1236A
Ying-Yue Bu,Hiroyuki Yamazaki,Kazuyo Ukai,Michio Namikoshi
Marine Drugs.2014;12(12)6102
[DOI]
43Bedaquiline and delamanid in tuberculosis
Susanna Esposito,Sonia Bianchini,Francesco Blasi
Expert Opinion on Pharmacotherapy.2015;16(15)2319
[DOI]
44Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)
Andréanne Lupien,Anthony Vocat,Caroline Shi-Yan Foo,Emilyne Blattes,Jean-Yves Gillon,Vadim Makarov,Stewart T. Cole
Antimicrobial Agents and Chemotherapy.2018;62(11)2319
[DOI]
45Development and validation of LC–MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood
Bhavesh D Patel,Ritika Uppal,Nageswararao Pulakundam,Jignesh P Patel,Vikram Ramanathan,Rakshit Ameta,Delphine Launay,Stéphanie Braillard
Bioanalysis.2019;11(15)1419
[DOI]
46Development and validation of LC–MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood
Chanchal Kumar,Kamal Shrivastava,Shraddha Gupta,Mandira Varma-Basil
Bioanalysis.2019;11(15)33
[DOI]
  Feedback 
  Subscribe